http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 29 Oct 2026 14:39:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++DR+REDDYS+LABORATORIES++++For%3A+Oct+29/27256850.html si-local-file:///var/storage/secattach/20261029/27256850.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++DR+REDDYS+LABORATORIES++++For%3A+Oct+29/27256850.html Thu, 29 Oct 2026 14:39:00 -0400 RDY http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++DR+REDDYS+LABORATORIES++++For%3A+Oct+28/27251710.html si-local-file:///var/storage/secattach/20261029/27251710.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++DR+REDDYS+LABORATORIES++++For%3A+Oct+28/27251710.html Thu, 29 Oct 2026 06:03:00 -0400 RDY http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++DR+REDDYS+LABORATORIES++++For%3A+Oct+24/27230209.html si-local-file:///var/storage/secattach/20261026/27230209.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++DR+REDDYS+LABORATORIES++++For%3A+Oct+24/27230209.html Mon, 26 Oct 2026 06:23:00 -0400 RDY http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++DR+REDDYS+LABORATORIES++++For%3A+Oct+24/27230198.html si-local-file:///var/storage/secattach/20261026/27230198.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++DR+REDDYS+LABORATORIES++++For%3A+Oct+24/27230198.html Mon, 26 Oct 2026 06:18:00 -0400 RDY http://www.streetinsider.com/Intl+Ratings/Dr.+Reddy%5C%27s+Laboratories+%28DRRD%3AIN%29+%28RDY%29+PT+Raised+to+INR1%2C220+at+Kotak/27229343.html <p>Kotak analyst Alankar Garude raised the price target on Dr. Reddy\'s Laboratories (DRRD:IN) (NYSE: RDY) to INR1,220.00 (from INR1,125.00) while maintaining a Reduce (3) rating.</p><p>The analyst comments: “After two successive quarters of tepid margins, DRRD delivered a strong comeback with an adjusted EBITDA margin of 19.1% (440 bps above KIE; +550 bps qoq) in 2QFY27, aided by new launches, a favorable business mix, the much-awaited cost efficiencies and forex tailwinds. Importantly, DRRD stays confident of restoring Semaglutide supplies by Nov-2026 and is guiding for ~20%+ IFRS EBITDA margins in 2HFY27E. While the 2HFY27 outlook is healthy, led by the likely http://www.streetinsider.com/Intl+Ratings/Dr.+Reddy%5C%27s+Laboratories+%28DRRD%3AIN%29+%28RDY%29+PT+Raised+to+INR1%2C220+at+Kotak/27229343.html Sun, 25 Oct 2026 10:51:46 -0400 RDY http://www.streetinsider.com/Analyst+PT+Change/Dr.+Reddy%5C%27s+Laboratories+%28DRRD%3AIN%29+%28RDY%29+PT+Raised+to+INR1%2C220+at+Kotak/27229343.html <p>Kotak analyst Alankar Garude raised the price target on Dr. Reddy\'s Laboratories (DRRD:IN) (NYSE: RDY) to INR1,220.00 (from INR1,125.00) while maintaining a Reduce (3) rating.</p><p>The analyst comments: “After two successive quarters of tepid margins, DRRD delivered a strong comeback with an adjusted EBITDA margin of 19.1% (440 bps above KIE; +550 bps qoq) in 2QFY27, aided by new launches, a favorable business mix, the much-awaited cost efficiencies and forex tailwinds. Importantly, DRRD stays confident of restoring Semaglutide supplies by Nov-2026 and is guiding for ~20%+ IFRS EBITDA margins in 2HFY27E. While the 2HFY27 outlook is healthy, led by the likely http://www.streetinsider.com/Analyst+PT+Change/Dr.+Reddy%5C%27s+Laboratories+%28DRRD%3AIN%29+%28RDY%29+PT+Raised+to+INR1%2C220+at+Kotak/27229343.html Sun, 25 Oct 2026 10:51:46 -0400 RDY http://www.streetinsider.com/Analyst+Comments/Dr.+Reddy%5C%27s+Laboratories+%28DRRD%3AIN%29+%28RDY%29+PT+Raised+to+INR1%2C220+at+Kotak/27229343.html <p>Kotak analyst Alankar Garude raised the price target on Dr. Reddy\'s Laboratories (DRRD:IN) (NYSE: RDY) to INR1,220.00 (from INR1,125.00) while maintaining a Reduce (3) rating.</p><p>The analyst comments: “After two successive quarters of tepid margins, DRRD delivered a strong comeback with an adjusted EBITDA margin of 19.1% (440 bps above KIE; +550 bps qoq) in 2QFY27, aided by new launches, a favorable business mix, the much-awaited cost efficiencies and forex tailwinds. Importantly, DRRD stays confident of restoring Semaglutide supplies by Nov-2026 and is guiding for ~20%+ IFRS EBITDA margins in 2HFY27E. While the 2HFY27 outlook is healthy, led by the likely http://www.streetinsider.com/Analyst+Comments/Dr.+Reddy%5C%27s+Laboratories+%28DRRD%3AIN%29+%28RDY%29+PT+Raised+to+INR1%2C220+at+Kotak/27229343.html Sun, 25 Oct 2026 10:51:46 -0400 RDY http://www.streetinsider.com/Intl+Ratings/Dr.+Reddy%5C%27s+Laboratories+%28DRRD%3AIN%29+%28RDY%29+PT+Raised+to+INR1%2C220+at+Kotak/27229343.html <p>Kotak analyst Alankar Garude raised the price target on Dr. Reddy\'s Laboratories (DRRD:IN) (NYSE: RDY) to INR1,220.00 (from INR1,125.00) while maintaining a Reduce (3) rating.</p><p>The analyst comments: “After two successive quarters of tepid margins, DRRD delivered a strong comeback with an adjusted EBITDA margin of 19.1% (440 bps above KIE; +550 bps qoq) in 2QFY27, aided by new launches, a favorable business mix, the much-awaited cost efficiencies and forex tailwinds. Importantly, DRRD stays confident of restoring Semaglutide supplies by Nov-2026 and is guiding for ~20%+ IFRS EBITDA margins in 2HFY27E. While the 2HFY27 outlook is healthy, led by the likely http://www.streetinsider.com/Intl+Ratings/Dr.+Reddy%5C%27s+Laboratories+%28DRRD%3AIN%29+%28RDY%29+PT+Raised+to+INR1%2C220+at+Kotak/27229343.html Sun, 25 Oct 2026 10:51:46 -0400 RDY http://www.streetinsider.com/Analyst+PT+Change/Dr.+Reddy%5C%27s+Laboratories+%28DRRD%3AIN%29+%28RDY%29+PT+Raised+to+INR1%2C220+at+Kotak/27229343.html <p>Kotak analyst Alankar Garude raised the price target on Dr. Reddy\'s Laboratories (DRRD:IN) (NYSE: RDY) to INR1,220.00 (from INR1,125.00) while maintaining a Reduce (3) rating.</p><p>The analyst comments: “After two successive quarters of tepid margins, DRRD delivered a strong comeback with an adjusted EBITDA margin of 19.1% (440 bps above KIE; +550 bps qoq) in 2QFY27, aided by new launches, a favorable business mix, the much-awaited cost efficiencies and forex tailwinds. Importantly, DRRD stays confident of restoring Semaglutide supplies by Nov-2026 and is guiding for ~20%+ IFRS EBITDA margins in 2HFY27E. While the 2HFY27 outlook is healthy, led by the likely http://www.streetinsider.com/Analyst+PT+Change/Dr.+Reddy%5C%27s+Laboratories+%28DRRD%3AIN%29+%28RDY%29+PT+Raised+to+INR1%2C220+at+Kotak/27229343.html Sun, 25 Oct 2026 10:51:46 -0400 RDY http://www.streetinsider.com/Analyst+Comments/Dr.+Reddy%5C%27s+Laboratories+%28DRRD%3AIN%29+%28RDY%29+PT+Raised+to+INR1%2C220+at+Kotak/27229343.html <p>Kotak analyst Alankar Garude raised the price target on Dr. Reddy\'s Laboratories (DRRD:IN) (NYSE: RDY) to INR1,220.00 (from INR1,125.00) while maintaining a Reduce (3) rating.</p><p>The analyst comments: “After two successive quarters of tepid margins, DRRD delivered a strong comeback with an adjusted EBITDA margin of 19.1% (440 bps above KIE; +550 bps qoq) in 2QFY27, aided by new launches, a favorable business mix, the much-awaited cost efficiencies and forex tailwinds. Importantly, DRRD stays confident of restoring Semaglutide supplies by Nov-2026 and is guiding for ~20%+ IFRS EBITDA margins in 2HFY27E. While the 2HFY27 outlook is healthy, led by the likely http://www.streetinsider.com/Analyst+Comments/Dr.+Reddy%5C%27s+Laboratories+%28DRRD%3AIN%29+%28RDY%29+PT+Raised+to+INR1%2C220+at+Kotak/27229343.html Sun, 25 Oct 2026 10:51:46 -0400 RDY http://www.streetinsider.com/Intl+Ratings/Dr.+Reddy%5C%27s+Laboratories+Ltd.+%28DRRD%3AIN%29+%28RDY%29+PT+Raised+to+INR1%2C235+at+Axis+Capital+Limited/27229341.html <p>Axis Capital Limited analyst Kunal Randeria raised the price target on Dr. Reddy\'s Laboratories Ltd. (DRRD:IN) (NYSE: RDY) to INR1,235.00 (from INR1,160.00) while maintaining a Reduce (3) rating.</p><p>The analyst comments: “Q2 sales/Adj.EBITDA/Adj.PAT -6/-49/-55% YoY, a 1/21/14% miss to consensus. Strong topline as all markets – N. America (USD264mn, +13% QoQ), India +17% YoY, EM +31% – showed strong growth. Adj. EBITDA margin at 18.6%, +~504bps QoQ largely on lower R&D. We flag that bosutinib is likely to fade, R&D/opex are likely to increase in coming Qs. Canada semaglutide re-launch is crucial in a market that is likely to be highly http://www.streetinsider.com/Intl+Ratings/Dr.+Reddy%5C%27s+Laboratories+Ltd.+%28DRRD%3AIN%29+%28RDY%29+PT+Raised+to+INR1%2C235+at+Axis+Capital+Limited/27229341.html Sun, 25 Oct 2026 10:50:20 -0400 RDY http://www.streetinsider.com/Analyst+PT+Change/Dr.+Reddy%5C%27s+Laboratories+Ltd.+%28DRRD%3AIN%29+%28RDY%29+PT+Raised+to+INR1%2C235+at+Axis+Capital+Limited/27229341.html <p>Axis Capital Limited analyst Kunal Randeria raised the price target on Dr. Reddy\'s Laboratories Ltd. (DRRD:IN) (NYSE: RDY) to INR1,235.00 (from INR1,160.00) while maintaining a Reduce (3) rating.</p><p>The analyst comments: “Q2 sales/Adj.EBITDA/Adj.PAT -6/-49/-55% YoY, a 1/21/14% miss to consensus. Strong topline as all markets – N. America (USD264mn, +13% QoQ), India +17% YoY, EM +31% – showed strong growth. Adj. EBITDA margin at 18.6%, +~504bps QoQ largely on lower R&D. We flag that bosutinib is likely to fade, R&D/opex are likely to increase in coming Qs. Canada semaglutide re-launch is crucial in a market that is likely to be highly http://www.streetinsider.com/Analyst+PT+Change/Dr.+Reddy%5C%27s+Laboratories+Ltd.+%28DRRD%3AIN%29+%28RDY%29+PT+Raised+to+INR1%2C235+at+Axis+Capital+Limited/27229341.html Sun, 25 Oct 2026 10:50:20 -0400 RDY http://www.streetinsider.com/Analyst+Comments/Dr.+Reddy%5C%27s+Laboratories+Ltd.+%28DRRD%3AIN%29+%28RDY%29+PT+Raised+to+INR1%2C235+at+Axis+Capital+Limited/27229341.html <p>Axis Capital Limited analyst Kunal Randeria raised the price target on Dr. Reddy\'s Laboratories Ltd. (DRRD:IN) (NYSE: RDY) to INR1,235.00 (from INR1,160.00) while maintaining a Reduce (3) rating.</p><p>The analyst comments: “Q2 sales/Adj.EBITDA/Adj.PAT -6/-49/-55% YoY, a 1/21/14% miss to consensus. Strong topline as all markets – N. America (USD264mn, +13% QoQ), India +17% YoY, EM +31% – showed strong growth. Adj. EBITDA margin at 18.6%, +~504bps QoQ largely on lower R&D. We flag that bosutinib is likely to fade, R&D/opex are likely to increase in coming Qs. Canada semaglutide re-launch is crucial in a market that is likely to be highly http://www.streetinsider.com/Analyst+Comments/Dr.+Reddy%5C%27s+Laboratories+Ltd.+%28DRRD%3AIN%29+%28RDY%29+PT+Raised+to+INR1%2C235+at+Axis+Capital+Limited/27229341.html Sun, 25 Oct 2026 10:50:20 -0400 RDY http://www.streetinsider.com/Intl+Ratings/Dr.+Reddy%5C%27s+Laboratories+Ltd.+%28DRRD%3AIN%29+%28RDY%29+PT+Raised+to+INR1%2C235+at+Axis+Capital+Limited/27229341.html <p>Axis Capital Limited analyst Kunal Randeria raised the price target on Dr. Reddy\'s Laboratories Ltd. (DRRD:IN) (NYSE: RDY) to INR1,235.00 (from INR1,160.00) while maintaining a Reduce (3) rating.</p><p>The analyst comments: “Q2 sales/Adj.EBITDA/Adj.PAT -6/-49/-55% YoY, a 1/21/14% miss to consensus. Strong topline as all markets – N. America (USD264mn, +13% QoQ), India +17% YoY, EM +31% – showed strong growth. Adj. EBITDA margin at 18.6%, +~504bps QoQ largely on lower R&D. We flag that bosutinib is likely to fade, R&D/opex are likely to increase in coming Qs. Canada semaglutide re-launch is crucial in a market that is likely to be highly http://www.streetinsider.com/Intl+Ratings/Dr.+Reddy%5C%27s+Laboratories+Ltd.+%28DRRD%3AIN%29+%28RDY%29+PT+Raised+to+INR1%2C235+at+Axis+Capital+Limited/27229341.html Sun, 25 Oct 2026 10:50:20 -0400 RDY http://www.streetinsider.com/Analyst+PT+Change/Dr.+Reddy%5C%27s+Laboratories+Ltd.+%28DRRD%3AIN%29+%28RDY%29+PT+Raised+to+INR1%2C235+at+Axis+Capital+Limited/27229341.html <p>Axis Capital Limited analyst Kunal Randeria raised the price target on Dr. Reddy\'s Laboratories Ltd. (DRRD:IN) (NYSE: RDY) to INR1,235.00 (from INR1,160.00) while maintaining a Reduce (3) rating.</p><p>The analyst comments: “Q2 sales/Adj.EBITDA/Adj.PAT -6/-49/-55% YoY, a 1/21/14% miss to consensus. Strong topline as all markets – N. America (USD264mn, +13% QoQ), India +17% YoY, EM +31% – showed strong growth. Adj. EBITDA margin at 18.6%, +~504bps QoQ largely on lower R&D. We flag that bosutinib is likely to fade, R&D/opex are likely to increase in coming Qs. Canada semaglutide re-launch is crucial in a market that is likely to be highly http://www.streetinsider.com/Analyst+PT+Change/Dr.+Reddy%5C%27s+Laboratories+Ltd.+%28DRRD%3AIN%29+%28RDY%29+PT+Raised+to+INR1%2C235+at+Axis+Capital+Limited/27229341.html Sun, 25 Oct 2026 10:50:20 -0400 RDY http://www.streetinsider.com/Analyst+Comments/Dr.+Reddy%5C%27s+Laboratories+Ltd.+%28DRRD%3AIN%29+%28RDY%29+PT+Raised+to+INR1%2C235+at+Axis+Capital+Limited/27229341.html <p>Axis Capital Limited analyst Kunal Randeria raised the price target on Dr. Reddy\'s Laboratories Ltd. (DRRD:IN) (NYSE: RDY) to INR1,235.00 (from INR1,160.00) while maintaining a Reduce (3) rating.</p><p>The analyst comments: “Q2 sales/Adj.EBITDA/Adj.PAT -6/-49/-55% YoY, a 1/21/14% miss to consensus. Strong topline as all markets – N. America (USD264mn, +13% QoQ), India +17% YoY, EM +31% – showed strong growth. Adj. EBITDA margin at 18.6%, +~504bps QoQ largely on lower R&D. We flag that bosutinib is likely to fade, R&D/opex are likely to increase in coming Qs. Canada semaglutide re-launch is crucial in a market that is likely to be highly http://www.streetinsider.com/Analyst+Comments/Dr.+Reddy%5C%27s+Laboratories+Ltd.+%28DRRD%3AIN%29+%28RDY%29+PT+Raised+to+INR1%2C235+at+Axis+Capital+Limited/27229341.html Sun, 25 Oct 2026 10:50:20 -0400 RDY http://www.streetinsider.com/Intl+Ratings/Jefferies+Upgrades+Dr.+Reddy%5C%27s+Laboratories+Ltd.+%28DRRD%3AIN%29+%28RDY%29+to+Hold/27229339.html <p>Jefferies analyst Alok Dalal upgraded Dr. Reddy\'s Laboratories Ltd. (DRRD:IN) (NYSE: RDY) from Underperform to Hold with a price target of INR1,320.00 (from INR1,040.00).</p><p>The analyst comments: “Dr Reddy's Sep-Q Ebitda beat our est by 15% despite in-line revenue. Core business of India and RoW remained strong while the US recovered QoQ. Dr Reddy's expects to resume supplies for Semaglutide in Nov'26 and US approval for bAbatacept in Dec'26. We increase FY28/29 EPS est by 5-7% to factor in the above and higher margins for the base business. At a PE valuation of 21x FY28E, we believe the downside is limited. http://www.streetinsider.com/Intl+Ratings/Jefferies+Upgrades+Dr.+Reddy%5C%27s+Laboratories+Ltd.+%28DRRD%3AIN%29+%28RDY%29+to+Hold/27229339.html Sun, 25 Oct 2026 10:46:45 -0400 RDY http://www.streetinsider.com/Upgrades/Jefferies+Upgrades+Dr.+Reddy%5C%27s+Laboratories+Ltd.+%28DRRD%3AIN%29+%28RDY%29+to+Hold/27229339.html <p>Jefferies analyst Alok Dalal upgraded Dr. Reddy\'s Laboratories Ltd. (DRRD:IN) (NYSE: RDY) from Underperform to Hold with a price target of INR1,320.00 (from INR1,040.00).</p><p>The analyst comments: “Dr Reddy's Sep-Q Ebitda beat our est by 15% despite in-line revenue. Core business of India and RoW remained strong while the US recovered QoQ. Dr Reddy's expects to resume supplies for Semaglutide in Nov'26 and US approval for bAbatacept in Dec'26. We increase FY28/29 EPS est by 5-7% to factor in the above and higher margins for the base business. At a PE valuation of 21x FY28E, we believe the downside is limited. http://www.streetinsider.com/Upgrades/Jefferies+Upgrades+Dr.+Reddy%5C%27s+Laboratories+Ltd.+%28DRRD%3AIN%29+%28RDY%29+to+Hold/27229339.html Sun, 25 Oct 2026 10:46:45 -0400 RDY http://www.streetinsider.com/Analyst+Comments/Jefferies+Upgrades+Dr.+Reddy%5C%27s+Laboratories+Ltd.+%28DRRD%3AIN%29+%28RDY%29+to+Hold/27229339.html <p>Jefferies analyst Alok Dalal upgraded Dr. Reddy\'s Laboratories Ltd. (DRRD:IN) (NYSE: RDY) from Underperform to Hold with a price target of INR1,320.00 (from INR1,040.00).</p><p>The analyst comments: “Dr Reddy's Sep-Q Ebitda beat our est by 15% despite in-line revenue. Core business of India and RoW remained strong while the US recovered QoQ. Dr Reddy's expects to resume supplies for Semaglutide in Nov'26 and US approval for bAbatacept in Dec'26. We increase FY28/29 EPS est by 5-7% to factor in the above and higher margins for the base business. At a PE valuation of 21x FY28E, we believe the downside is limited. http://www.streetinsider.com/Analyst+Comments/Jefferies+Upgrades+Dr.+Reddy%5C%27s+Laboratories+Ltd.+%28DRRD%3AIN%29+%28RDY%29+to+Hold/27229339.html Sun, 25 Oct 2026 10:46:45 -0400 RDY http://www.streetinsider.com/Intl+Ratings/Jefferies+Upgrades+Dr.+Reddy%5C%27s+Laboratories+Ltd.+%28DRRD%3AIN%29+%28RDY%29+to+Hold/27229339.html <p>Jefferies analyst Alok Dalal upgraded Dr. Reddy\'s Laboratories Ltd. (DRRD:IN) (NYSE: RDY) from Underperform to Hold with a price target of INR1,320.00 (from INR1,040.00).</p><p>The analyst comments: “Dr Reddy's Sep-Q Ebitda beat our est by 15% despite in-line revenue. Core business of India and RoW remained strong while the US recovered QoQ. Dr Reddy's expects to resume supplies for Semaglutide in Nov'26 and US approval for bAbatacept in Dec'26. We increase FY28/29 EPS est by 5-7% to factor in the above and higher margins for the base business. At a PE valuation of 21x FY28E, we believe the downside is limited. http://www.streetinsider.com/Intl+Ratings/Jefferies+Upgrades+Dr.+Reddy%5C%27s+Laboratories+Ltd.+%28DRRD%3AIN%29+%28RDY%29+to+Hold/27229339.html Sun, 25 Oct 2026 10:46:45 -0400 RDY http://www.streetinsider.com/Upgrades/Jefferies+Upgrades+Dr.+Reddy%5C%27s+Laboratories+Ltd.+%28DRRD%3AIN%29+%28RDY%29+to+Hold/27229339.html <p>Jefferies analyst Alok Dalal upgraded Dr. Reddy\'s Laboratories Ltd. (DRRD:IN) (NYSE: RDY) from Underperform to Hold with a price target of INR1,320.00 (from INR1,040.00).</p><p>The analyst comments: “Dr Reddy's Sep-Q Ebitda beat our est by 15% despite in-line revenue. Core business of India and RoW remained strong while the US recovered QoQ. Dr Reddy's expects to resume supplies for Semaglutide in Nov'26 and US approval for bAbatacept in Dec'26. We increase FY28/29 EPS est by 5-7% to factor in the above and higher margins for the base business. At a PE valuation of 21x FY28E, we believe the downside is limited. http://www.streetinsider.com/Upgrades/Jefferies+Upgrades+Dr.+Reddy%5C%27s+Laboratories+Ltd.+%28DRRD%3AIN%29+%28RDY%29+to+Hold/27229339.html Sun, 25 Oct 2026 10:46:45 -0400 RDY http://www.streetinsider.com/Analyst+Comments/Jefferies+Upgrades+Dr.+Reddy%5C%27s+Laboratories+Ltd.+%28DRRD%3AIN%29+%28RDY%29+to+Hold/27229339.html <p>Jefferies analyst Alok Dalal upgraded Dr. Reddy\'s Laboratories Ltd. (DRRD:IN) (NYSE: RDY) from Underperform to Hold with a price target of INR1,320.00 (from INR1,040.00).</p><p>The analyst comments: “Dr Reddy's Sep-Q Ebitda beat our est by 15% despite in-line revenue. Core business of India and RoW remained strong while the US recovered QoQ. Dr Reddy's expects to resume supplies for Semaglutide in Nov'26 and US approval for bAbatacept in Dec'26. We increase FY28/29 EPS est by 5-7% to factor in the above and higher margins for the base business. At a PE valuation of 21x FY28E, we believe the downside is limited. http://www.streetinsider.com/Analyst+Comments/Jefferies+Upgrades+Dr.+Reddy%5C%27s+Laboratories+Ltd.+%28DRRD%3AIN%29+%28RDY%29+to+Hold/27229339.html Sun, 25 Oct 2026 10:46:45 -0400 RDY http://www.streetinsider.com/Intl+Ratings/JPMorgan+Upgrades+Dr.+Reddy%5C%27s+Laboratories+%28DRRD%3AIN%29+%28RDY%29+to+Neutral/27229320.html <p>JPMorgan analyst Bansi Desai upgraded Dr. Reddy\'s Laboratories (DRRD:IN) (NYSE: RDY) from Underweight to Neutral with a price target of INR1,270.00 (from INR1,100.00).</p><p>The analyst comments: “We are closing our UW after almost four years as the stock has underperformed (-3% YTD vs. Nifty Pharma Index +11%) and the risk reward now looks more balanced. 2Q was a revenue miss, but adj core margins at 19.5% beat JPMe by ~160bps, driven by below-normal R&D (100–200bps lower), contained SG&A and low-margin PSAI down 12% YoY, so durability remains to be seen. We remain conservative on the semaglutide ramp, and abatacept approval and http://www.streetinsider.com/Intl+Ratings/JPMorgan+Upgrades+Dr.+Reddy%5C%27s+Laboratories+%28DRRD%3AIN%29+%28RDY%29+to+Neutral/27229320.html Sun, 25 Oct 2026 10:25:11 -0400 RDY http://www.streetinsider.com/Upgrades/JPMorgan+Upgrades+Dr.+Reddy%5C%27s+Laboratories+%28DRRD%3AIN%29+%28RDY%29+to+Neutral/27229320.html <p>JPMorgan analyst Bansi Desai upgraded Dr. Reddy\'s Laboratories (DRRD:IN) (NYSE: RDY) from Underweight to Neutral with a price target of INR1,270.00 (from INR1,100.00).</p><p>The analyst comments: “We are closing our UW after almost four years as the stock has underperformed (-3% YTD vs. Nifty Pharma Index +11%) and the risk reward now looks more balanced. 2Q was a revenue miss, but adj core margins at 19.5% beat JPMe by ~160bps, driven by below-normal R&D (100–200bps lower), contained SG&A and low-margin PSAI down 12% YoY, so durability remains to be seen. We remain conservative on the semaglutide ramp, and abatacept approval and http://www.streetinsider.com/Upgrades/JPMorgan+Upgrades+Dr.+Reddy%5C%27s+Laboratories+%28DRRD%3AIN%29+%28RDY%29+to+Neutral/27229320.html Sun, 25 Oct 2026 10:25:11 -0400 RDY http://www.streetinsider.com/Analyst+Comments/JPMorgan+Upgrades+Dr.+Reddy%5C%27s+Laboratories+%28DRRD%3AIN%29+%28RDY%29+to+Neutral/27229320.html <p>JPMorgan analyst Bansi Desai upgraded Dr. Reddy\'s Laboratories (DRRD:IN) (NYSE: RDY) from Underweight to Neutral with a price target of INR1,270.00 (from INR1,100.00).</p><p>The analyst comments: “We are closing our UW after almost four years as the stock has underperformed (-3% YTD vs. Nifty Pharma Index +11%) and the risk reward now looks more balanced. 2Q was a revenue miss, but adj core margins at 19.5% beat JPMe by ~160bps, driven by below-normal R&D (100–200bps lower), contained SG&A and low-margin PSAI down 12% YoY, so durability remains to be seen. We remain conservative on the semaglutide ramp, and abatacept approval and http://www.streetinsider.com/Analyst+Comments/JPMorgan+Upgrades+Dr.+Reddy%5C%27s+Laboratories+%28DRRD%3AIN%29+%28RDY%29+to+Neutral/27229320.html Sun, 25 Oct 2026 10:25:11 -0400 RDY